Samsung Biologics, Vir partner on SARS-CoV-2 program

By The Science Advisory Board staff writers

April 10, 2020 -- Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody (mAb) program for a potential COVID-19 treatment.

Vir's lead SARS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays, according to the companies.

Within the next three to five months, Vir plans to proceed directly into a phase II clinical trial. Samsung Biologics is expected to begin manufacturing as early as October. Commercial batches may be manufactured starting in 2021, according to the companies.

The approximately $362 million deal between the companies builds on Vir's previously announced manufacturing agreement with WuXi Biologics and its letter of intent with Biogen.

New antiviral drug could work against many viruses, including SARS-CoV-2
An antiviral drug called EIDD-2801 that's in preclinical testing has potential to be developed into the silver bullet that medical professionals seek...
It's time to enlist research labs in the COVID-19 fight
Careful incorporation of research laboratories into the COVID-19 testing effort could increase capacity in the U.S. and globally, writes molecular diagnostics...
Generation Bio, Vir partner for mAbs against COVID-9
Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes...
Xencor, Vir partner on COVID-19 antibodies research
Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments...
Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter